Glomerulonephritis Clinical Trial
Official title:
Effect of Urine Alkalinazation on Urinary Inflammatory Markers Analyzed Using Mass Spectrometry in Patients With Cystinuria
It has recently been described the presence of a urinary inflammatory signature in patients with cystinuria, the most common cause of renal lithiasis of genetical origin. These data are very innovative in this pathology but deserve further studies to establish the specificity of this inflammatory signature in patients with cystinuria compared to other nephropathies and other renal lithiasis diseases. Moreover, the effect of the usual treatment of cystinuria (namely urine alkalanization) on urinary inflammatory biomarkers deserves to be tested. The objectives of the present study are: i) To study the urinary inflammatory profile by mass spectrometry (a very efficient tool to detect and identify proteins) in patients with cystinuria and in patients with lithiasis of other origin and in patients with inflammatory renal disease ; ii) To study the potential effect of urine alkalinazation with potassium citrate (usual treatment according to European recommendations) on the inflammatory signature of patients with cystinuria. To this aim, urine of non treated cystinuric patients will be collected before treatement initiation and 3 months after the start of the alkalizing treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001457 -
Lamivudine for Chronic Hepatitis B
|
Phase 2 | |
| Recruiting |
NCT05505955 -
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
|
Phase 1 | |
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Active, not recruiting |
NCT05174221 -
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
|
Phase 1 | |
| Completed |
NCT00426348 -
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
|
Phase 4 | |
| Recruiting |
NCT04662723 -
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
|
Phase 4 | |
| Completed |
NCT02700516 -
Recurrent Glomerulonephritis After Renal Transplantation
|
N/A | |
| Recruiting |
NCT00862693 -
Calcitriol in the Treatment of Immunoglobulin A Nephropathy
|
Phase 4 | |
| Completed |
NCT00983034 -
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
|
N/A | |
| Completed |
NCT00004990 -
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
|
Phase 2 | |
| Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 | |
| Terminated |
NCT04387448 -
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
|
Phase 2 | |
| Terminated |
NCT04950114 -
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
|
Phase 2 | |
| Completed |
NCT00437463 -
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
|
Phase 3 | |
| Terminated |
NCT02523768 -
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
|
Phase 4 | |
| Completed |
NCT00106561 -
Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
|
Phase 2/Phase 3 | |
| Completed |
NCT04733040 -
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)
|
Phase 2 | |
| Completed |
NCT00001676 -
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
|
Phase 1 | |
| Recruiting |
NCT02063100 -
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
|
Phase 4 | |
| Completed |
NCT01093157 -
A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
|
Phase 1/Phase 2 |